Skip to main content

Table 3 Disease characteristics

From: EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex

Disease characteristics Everolimus
N  =  120
Time since TSC diagnosis, median (range), years 9.1 (0.2–30.7)
Time since SEGA diagnosis, median (range), years 3.8 (0–24)
Modified Gomez criteria - major features, n (%)
 Facial angiofibromas or forehead plaques 93 (77.5)
 Non-traumatic ungual or periungual fibroma 18 (15.0)
 Hypomelanotic macules (3 or more) 95 (79.2)
 Shagreen patch (connective tissue nevus) 47 (39.2)
 Multiple retinal nodular hamartomas 23 (19.2)
 Cortical tuber 106 (88.3)
 Subependymal nodule 102 (85.0)
 Subependymal giant cell astrocytoma 120 (100.0)
 Cardiac rhabdomyoma, single or multiple 55 (45.8)
 Lymphangioleiomyomatosis 2 (1.7)
 Renal angiomyolipoma 59 (49.2)
Modified Gomez criteria - minor features, n (%)
 Multiple, randomly distributed pits in dental enamel 6 (5.0)
 Hamartomatous rectal polyps 0 (0.0)
 Bone cysts 2 (1.7)
 Cerebral white matter radial migration lines 16 (13.3)
 Gingival fibromas 6 (5.0)
 Non-renal hamartoma 3 (2.5)
 Retinal achromic patch 4 (3.3)
 'Confetti' skin lesions 15 (12.5)
 Multiple renal cysts 19 (15.8)
  1. SEGA subependymal giant cell astrocytoma, TSC tuberous sclerosis complex